Lmr Partners LLP Vor Biopharma Inc. Transaction History

Lmr Partners LLP

$10.5 Billion
Q2 2025

A detailed history of Lmr Partners LLP transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 50,000 shares of VOR stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,000

Holding current value

$1.41 Million

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.0 - $2.2 $10,214 - $22,470	10,214 Added 24.97%	51,111 $51,000
Q1 2024 May 15, 2024	SELL	$1.8 - $2.85 $18,385 - $29,109	-10,214 Reduced 19.98%	40,897 $96,000
Q4 2023 Feb 14, 2024	BUY	$1.66 - $2.63 $3,869 - $6,130	2,331 Added 4.78%	51,111 $114,000
Q2 2023 Aug 14, 2023	SELL	$3.09 - $5.33 $35,590 - $61,390	-11,518 Reduced 19.1%	48,780 $150,000
Q1 2023 May 15, 2023	BUY	$4.68 - $6.96 $80,177 - $119,238	17,132 Added 39.69%	60,298 $324,000
Q4 2022 Feb 14, 2023	BUY	$3.77 - $7.43 $61,820 - $121,837	16,398 Added 61.26%	43,166 $287,000
Q2 2022 Aug 15, 2022	BUY	$3.89 - $6.44 $26,327 - $43,585	6,768 Added 33.84%	26,768 $133,000
Q1 2022 May 16, 2022	BUY	$6.04 - $12.23 $120,800 - $244,600	20,000 New	20,000 $121,000

Others Institutions Holding VOR

# of Institutions

Shares Held

55.7M

Call Options Held

4.15M

Put Options Held

364K

Ra Capital Management, L.P. Boston, MA

39.6M
Shares

$1.12 Billion
1.4% of portfolio
5 Am Venture Management, LLC San Francisco, CA

6.36M
Shares

$179 Million
6.91% of portfolio
Vanguard Group Inc Valley Forge, PA

1.92M
Shares

$53.9 Million
0.0% of portfolio
Ubs Group Ag

1.53M
Shares

$43.1 Million
0.0% of portfolio
Johnson & Johnson New Brunswick, NJ

1.07M
Shares

$30.3 Million
0.59% of portfolio

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $1.07B
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account